gallo pinto
Selected indexed studies
- Empagliflozin in Patients with Chronic Kidney Disease. (N Engl J Med, 2023) [PMID:36331190]
- Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease. (N Engl J Med, 2025) [PMID:39453837]
- Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. (Lancet Diabetes Endocrinol, 2024) [PMID:38061371]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study. (2021) pubmed
- Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. (2021) pubmed
- Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. (2024) pubmed
- Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. (2024) pubmed
- Empagliflozin in Patients with Chronic Kidney Disease. (2023) pubmed
- Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease. (2025) pubmed
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. (1996) pubmed
- Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial. (2024) pubmed
- Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries. (2023) pubmed
- Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction. (2024) pubmed